Nectar Lifesciences Limited (NECLIFE) fundamentals
Nectar Lifesciences Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as NECLIFE (ISIN INE023H01027). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Nectar Lifesciences Limited does
Nectar Lifesciences Limited is an India-based pharmaceutical company. The Company's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The Company offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.
Valuation and market data
| Last close | ₹11.50 |
|---|---|
| Market capitalisation | ₹49 crore |
| Enterprise value | ₹-50 crore |
| P/E (TTM) | 0.00 |
| Price to book | 0.08 |
| Price to sales (TTM) | 10.34 |
| Book value per share | ₹136.05 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Jul 18 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹9 crore | ₹-88 crore | ₹-57 crore | -13.40 |
| Mar 2025 | ₹2 crore | ₹1 crore | ₹1 crore | -5.07 |
| Mar 2024 | ₹1,699 crore | ₹18 crore | ₹5 crore | 0.22 |
| Mar 2023 | ₹1,567 crore | ₹-41 crore | ₹-22 crore | -1.00 |
| Mar 2022 | ₹1,680 crore | ₹34 crore | ₹25 crore | 1.13 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 51.8% |
|---|---|
| Foreign institutions (FII) | 0.5% |
| Mutual funds | 0.0% |
| Other domestic institutions | 3.7% |
| Retail and others | 43.9% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.